Earendil: A Blueprint for a Multipolar Life Sciences Era
The $787M financing points to a new global architecture in biotech
False
The $787M financing points to a new global architecture in biotech
False
False
November 19, 2026
5 min read
AI could soon allow scientists to model a drug’s journey from molecular structure through manufacturing to how it behaves in patient
November 19, 2026
12 min read
Higher real yields are putting renewed pressure on early-stage biotech, increasing the appeal of China’s pipeline of drugs already in clinical development
November 18, 2026
6 min read
Niamh Chaney examines how agentic systems could help development teams manage complex workflows while keeping scientific judgment and accountability firmly with people
November 17, 2026
6 min read
Regeneron’s Andres Sirulnik reflects on the experiences that took him from treating leukemia patients to developing medicines – and why following the science still means putting patients first
False
Affiliations:
Specialties:
Areas of Expertise:
4 Topic Commentaries
Earendil: A Blueprint for a Multipolar Life Sciences Era
Julio Frenk, MD, MPH, PhD
Global health policy and health systems
•Harvard University
Nalini Anand, JD, MPH
Global health policy and research administration
•Georgetown University
Andrew Forsyth, PhD
Global health research policy and analytics
•Fogarty International Center, National Institutes of Health
Cassidy R. Sugimoto, PhD
Science of science and science policy
•Georgia Institute of Technology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.